We serve Chemical Name:LEMON OIL CAS:68648-39-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:LEMON OIL
CAS.NO:68648-39-5
Synonyms:EINECS 284-515-8
Molecular Formula:N/A
Molecular Weight:N/A
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:176 °C(lit.)
Density:0.853 g/mL at 25 °C
Index of Refraction:n20/D 1.4745(lit.)
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1993 3/PG 3
Packing Group:
Contact us for information like EINECS 284-515-8 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 284-515-8 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 284-515-8 Use and application,EINECS 284-515-8 technical grade,usp/ep/jp grade.
Related News: Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. LEMON OIL manufacturer Taiwan is denying entry to Chinese nationals from Guangdong, a southern coastal province that has also been battered by the virus, and travelers who have recently visited the area. LEMON OIL supplier Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). LEMON OIL vendor Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. LEMON OIL factory Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov.